Sign In
Buy MRK
$113.87
-1.62 (-1.40%)
At Close: Jun 18, 2026
RAHWAY, N.J.--(BUSINESS WIRE)--FDA Grants Breakthrough Therapy Designation to sac-TMT for Certain Patients With Advanced or Metastatic Nonsquamous NSCLC With EGFR Mutations.
The Smartest Dividend Stocks to Buy With $3,000 Right Now
04:10am, Thursday, 28'th Nov 2024
Need dividends? The highest-yielding stocks aren't necessarily your best choice.
Merck Stock Up as Winrevair Meets Goal in Advanced PAH Study
04:00pm, Tuesday, 26'th Nov 2024
MRK's study of PAH drug Winrevair in a more advanced form of the disease shows overwhelming efficacy.
Merck to Participate in the Citi 2024 Global Healthcare Conference
06:45am, Tuesday, 26'th Nov 2024
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Citi 2024 Global Healthcare Conference.
Why Is Merck Stock Trading Higher On Monday?
12:02pm, Monday, 25'th Nov 2024
On Monday, Merck & Co Inc MRK revealed topline results from the Phase 3 ZENITH study evaluating Winrevair (sotatercept-csrk) in adults with pulmonary arterial hypertension (PAH, WHO Group 1) function
Nvidia's Profit Ruled Last Quarter — Now It's These 8 Stocks' Turn
08:00am, Monday, 25'th Nov 2024
Nvidia reported third-quarter profit that doubled — putting it near the top of the S&P 500's growth. But look for profit growth elsewhere.
Merck's therapy for rare lung condition shown to help reduce risk of death in study
06:47am, Monday, 25'th Nov 2024
Merck said on Monday its drug, Winrevair, helped significantly reduce the risk of death in patients with a rare condition which causes high blood pressure in the lungs, months after it secured approva
Merck Announces Pivotal Phase 3 ZENITH Trial Evaluating WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint at Interim Analysis
06:45am, Monday, 25'th Nov 2024
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces Pivotal Phase 3 ZENITH Trial Evaluating WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint at Interim Analysis.
Merck Recommends Rejection of TRC Capital's “Mini-Tender” Offer
04:17pm, Friday, 22'nd Nov 2024
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Recommends Rejection of TRC Capital's “Mini-Tender” Offer.
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
10:01am, Friday, 22'nd Nov 2024
Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Not A Banana: 2 (Special) Dividend Stocks Offering Ultra-Deep Value
07:30am, Friday, 22'nd Nov 2024
In today's market, many investors are distracted by hype. But the real value lies in stocks that provide strong, consistent dividend yields without the noise. Instead of chasing the latest trends, foc
Merck to Participate in the 7th Annual Evercore ISI HealthCONx Conference
07:15am, Friday, 22'nd Nov 2024
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the 7th Annual Evercore ISI HealthCONx Conference.
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's WELIREG Approved in China for the Treatment of Adult Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors.
Surendralal Karsanbhai Elected to Merck Board of Directors
06:30am, Friday, 22'nd Nov 2024
RAHWAY, N.J.--(BUSINESS WIRE)--Surendralal Karsanbhai Elected to Merck Board of Directors.
Merck Stock Trades Near 52-Week Low: What's Next for Investors?
04:00pm, Thursday, 21'st Nov 2024
We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.
